You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

List of Excipients in API sufentanil


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing sufentanil

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 ANHYDROUS DIBASIC CALCIUM PHOSPHATE
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 CROSCARMELLOSE SODIUM
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 FD&C BLUE NO. 2
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 HYPROMELLOSE
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 MAGNESIUM STEARATE
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 MANNITOL
AcelRx Pharmaceuticals Inc DSUVIA sufentanil 61621-430 STEARIC ACID
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Excipients in ANDA-approved (generic) drugs containing sufentanil

Company Ingredient NDC Excipient
Hospira Inc sufentanil citrate 0409-3382 HYDROCHLORIC ACID
Hospira Inc sufentanil citrate 0409-3382 SODIUM HYDROXIDE
Hospira Inc sufentanil citrate 0409-3382 WATER
West-Ward Pharmaceuticals Corp sufentanil citrate 0641-6110 CITRIC ACID MONOHYDRATE
West-Ward Pharmaceuticals Corp sufentanil citrate 0641-6110 WATER
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for sufentanil

Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE

Excipient focus: CITRIC ACID MONOHYDRATE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: FD&C BLUE NO. 2

Excipient focus: HYDROCHLORIC ACID

Excipient focus: HYPROMELLOSE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MANNITOL

Excipient focus: SODIUM HYDROXIDE

Excipient focus: STEARIC ACID

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group